Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma

Br J Dermatol. 2021 Feb;184(2):345-347. doi: 10.1111/bjd.19470. Epub 2020 Sep 20.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes
  • Humans
  • Infliximab
  • Lymphoma, T-Cell, Cutaneous* / drug therapy
  • Neoplasm Recurrence, Local / drug therapy
  • Nivolumab / therapeutic use
  • Skin Neoplasms* / drug therapy

Substances

  • Nivolumab
  • Infliximab